Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective decreased by Guggenheim from $935.00 to $900.00 in a research report sent to investors on Monday morning, FlyOnTheWall reports. Several other brokerages have also recently weighed in on REGN. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $915.00 to […]
Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,752 shares of the biopharmaceutical company’s stock after acquiring an additional 319 shares during […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $716.88, for a total transaction of $71,688.00. Following the completion of the transaction, the director now directly owns 18,747 […]
Freedom Day Solutions LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 3.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,152 shares of the biopharmaceutical company’s stock after acquiring an additional 64 shares during the quarter. […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $716.88, for a total transaction of $71,688.00. Following the completion of the sale, the director now owns 18,747 shares […]